Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis

Overview

Evaluate the effect of high dose MTX on skin induration in patients with eosinophilic fascia.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2010

Detailed Description

Eosinophilic fasciitis (EF)is a fibrosing skin disorder extensively involving the deep fascia. The aim of this pilot study is to evaluate the effect of high dose MTX on skin induration in patients with EF. In addition, we study the effect of this treatment on joint mobility, peripheral blood eosinophilia, functional ability, and pulmonary function. By administering high dose MTX intravenously every four weeks with a Leukovorin rescue, we hope to induce a more pronounced and sustained effect on the involved skin with less (long-lasting) side effects.

Interventions

  • Drug: methotrexate
    • methotrexate

Clinical Trial Outcome Measures

Primary Measures

  • Efficacy is evaluated after 6 months.
    • Time Frame: December 2008

Participating in This Clinical Trial

Inclusion Criteria

  • Eosinophilic fasciitis as defined by clinical judgement of an expert, – Histologically confirmed with a skin-fascia-muscle biopsy, and in additon: – Either the presence of a modified skin score according to Zachariae of 8 or higher (0-18), regarded as a generalised eosinophilic fasciitis or the presence of severe contractures due to eosinophilic fasciitis lesions. Exclusion Criteria:

  • Age < 18 yrs – Contraindications to MTX: AST/ALT level > 2 times upper limit of normal, WBC count < 3.5 x 109/l or platelet count < 150 x 109/l, serum creatinine > 130 micromol/l or clearance < 50 ml/min, confirmed by two repeated tests within one month. – Chronic liver disease, insulin dependant diabetes mellitus, alcohol abuse – Restrictive pulmonary disease (total lung capacity or vital capacity < 40% of predicted) or interstitial lung disease (KCO < 60% of predicted) – Pregnancy or child bearing potential without adequate contraception – The presence of any serious co-morbidity or malignancy – Use of other anti-folate drugs than MTX

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Radboud University Medical Center
  • Provider of Information About this Clinical Study
    • H. Knaapen, MD, Radboud University
  • Overall Official(s)
    • H. Knaapen, MD, Principal Investigator, Radboud University Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.